EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management

Satapathy, Shraddhanjali; Singh, Varsha; Nambirajan, Aruna; Malik, Prabhat Singh; Tanwar, Pranay; Mehta, Anurag; Suryavanshi, Moushumi; Thulkar, Sanjay; Mohan, Anant; Jain, Deepali

doi:10.1016/j.currproblcancer.2021.100722

Cited by 9 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies demonstrated the potential of ctDNA analysis for risk profiling, disease management or monitoring of NSCLC 140‐154 . Good concordance between urinary cfDNA and matched plasma (70.0%) or tissue biopsies (84.0%‐93.0%) was shown in patients with all different stages of lung cancer 144‐149 . The potential of cfDNA targeting ALU repeats 140 and LINE1 fragments 141 at different sizes was demonstrated for the diagnosis of lung cancer.…”

Section: Resultsmentioning

confidence: 99%

“…Various studies demonstrated the potential of ctDNA analysis for risk profiling, disease management or monitoring of NSCLC. [140][141][142][143][144][145][146][147][148][149][150][151][152][153][154] Good concordance between urinary cfDNA and matched plasma (70.0%) or tissue biopsies (84.0%-93.0%) was shown in patients with all different stages of lung cancer. [144][145][146][147][148][149] The potential of cfDNA targeting ALU repeats 140 and LINE1 fragments 141 at different sizes was demonstrated for the diagnosis of lung cancer.…”

Section: Lung Cancermentioning

confidence: 98%

“…[140][141][142][143][144][145][146][147][148][149][150][151][152][153][154] Good concordance between urinary cfDNA and matched plasma (70.0%) or tissue biopsies (84.0%-93.0%) was shown in patients with all different stages of lung cancer. [144][145][146][147][148][149] The potential of cfDNA targeting ALU repeats 140 and LINE1 fragments 141 at different sizes was demonstrated for the diagnosis of lung cancer. Differences in genetic profiles of cfDNA were investigated in sputum (74.0%), plasma (86.0%) and urine (70.0%), a good correlation and complementarity to tissue was demonstrated.…”

Section: Lung Cancermentioning

confidence: 98%

See 2 more Smart Citations

Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods

Jordaens

Zwaenepoel

Tjalma

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

The aim of this review was to explore the status of urine sampling as a liquid biopsy for noninvasive cancer research by reviewing used preanalytical parameters and protocols.We searched two main health sciences databases, PubMed and Web of Science. From all eligible publications (2010-2022), information was extracted regarding: (a) study population characteristics, (b) cancer type, (c) urine preanalytics, (d) analyte class, (e) isolation method, (f ) detection method, (g) comparator used, (h) biomarker type, (i) conclusion and (j) sensitivity and specificity. The search query identified 7835 records, of which 924 unique publications remained after screening the title, abstract and full text. Our analysis demonstrated that many publications did not report information about the preanalytical parameters of their urine samples, even though several other studies have shown the importance of standardization of sample handling. Interestingly, it was noted that urine is used for many cancer types and not just cancers originating from the urogenital tract. Many different types of relevant analytes have been shown to be found in urine. Additionally, future considerations and recommendations are discussed: (a) the heterogeneous nature of urine, (b) the need for standardized practice protocols and (c) the road toward the clinic. Urine is an emerging liquid biopsy with broad applicability in different analytes and several cancer types. However, standard

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Lung Cancermentioning

confidence: 98%

Section: Lung Cancermentioning

confidence: 98%

See 1 more Smart Citation

Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods

Jordaens

Zwaenepoel

Tjalma

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Satapathy et al 83 to be significantly higher in tear exosomes collected from metastatic breast cancer patients compared to healthy volunteers. 104 This study also revealed that the tear exosomal markers, CD9 and CD63, were significantly expressed in higher quantities compared to serum exosomes, which could be due to the loss of exosomes during the serum sample preparation.…”

Section: Liquid Biopsies: Tearsmentioning

confidence: 95%

Multiomic Approaches for Cancer Biomarker Discovery in Liquid Biopsies: Advances and Challenges

Diaz,

Leehans,

Ravishankar

et al. 2023

Biomark�Insights

View full text Add to dashboard Cite

Cancer is a complex and heterogeneous disease that poses a significant threat to global health. Early diagnosis and treatment are critical for improving patient outcomes, and the use of liquid biopsies has emerged as a promising approach for cancer detection and monitoring. Traditionally, cancer diagnosis has relied on invasive tissue biopsies, the collection of which can prove challenging for patients and the results of which may not always provide accurate results due to tumor heterogeneity. Liquid biopsies have gained increasing attention as they provide a non-invasive and accessible source of cancer biomarkers, which can be used to diagnose cancer, monitor treatment response, and detect relapse. The integration of -omics technologies, such as proteomics, genomics, and metabolomics, has further enhanced the capabilities of liquid biopsies by introducing precision oncology and enabling the tailoring of treatment for individual patients based on their unique tumor biology. In this review, we will discuss the challenges and advances in the field of cancer liquid biopsies and the integration of -omics technologies for different types of liquid biopsies, including blood, tear, urine, sweat, saliva, and cerebrospinal fluid.

show abstract

“…ctDNA can be extracted from a variety of bodily fluids, including saliva, sputum, CSF, urine, and pleural secretions, in addition to plasma [105,106]. Despite its moderate sensitivity, urine ctDNA is a viable alternative for detecting EGFR mutations [107]. With a concordance of 84.62% among all patients, [108] tissue biopsy and liquid biopsy using ctDNA can have distinct effects on the prognosis and treatment strategies of EGFR mutant non-small cell lung adenocarcinoma.…”

Section: Liquid Biopsy In Egfr Mutant Nsclc Detection Comparative Sup...mentioning

confidence: 99%

Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers

et al. 2022

View full text Add to dashboard Cite

The advent of molecular profiling has revolutionized the treatment of lung cancer by comprehensively delineating the genomic landscape of the epidermal growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters impedes effective treatment of EGFR mutant and resistant lung cancer. This review appraises current literature, opportunities, and challenges associated with liquid biopsy and pharmacogenomic (PGx) testing as precision therapy tools in the management of EGFR mutant and resistant lung cancers. Liquid biopsy could play a potential role in selection of precise tyrosine kinase inhibitor (TKI) therapies during different phases of lung cancer treatment. This selection will be based on the driver EGFR mutational status, as well as monitoring the development of potential EGFR mutations arising during or after TKIs treatment, since some of these new mutations may be druggable targets for alternative TKIs. Several studies have identified the utility of liquid biopsy in the identification of EGFR driver and acquired resistance with good sensitivities for various blood-based biomarkers. With a plethora of sequencing technologies and platforms available currently, further evaluations using randomized controlled trials (RCTs) in multicentric, multiethnic and larger patient cohorts could enable optimization of liquid-based assays for the detection of EGFR mutations, and support testing of CYP450 enzymes and drug transporter polymorphisms to guide precise dosing of EGFR TKIs.

show abstract

EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management

Cited by 9 publications

References 44 publications

Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods

Urine biomarkers in cancer detection: A systematic review of preanalytical parameters and applied methods

Multiomic Approaches for Cancer Biomarker Discovery in Liquid Biopsies: Advances and Challenges

Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers

Contact Info

Product

Resources

About